Clinical Trial Search

Phase 3 N=750 Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma · Ocular Hypertension

Primary: Intraocular Pressure (IOP) — 24.69; 24.66; 24.75; 23.33 mmHg — p=<0.0001

Aerie Pharmaceuticals Results May 2019 1.7% serious AE View details

Phase 3 N=553 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms · Platinum Sensitive Ovarian Cancer

Primary: Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA) — 21; 5.5 months — p=<0.0001

Tesaro, Inc. Results May 2019 24.9% serious AE View details

Phase 3 N=218 BAX 855 Continuation

Hemophilia A

Primary: Number of Participants With Inhibitory Antibodies to Factor VIII (FVIII) — 0; 0; 0; 0 Participants

Baxalta now part of Shire Results May 2019 15.3% serious AE View details

Phase 3 N=98 Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children

Short Stature

Primary: The Proportion of Children Maintaining Normal Growth Velocity — 23; 32; 31 Participants

Göteborg University Results Apr 2019 10.2% serious AE View details

Phase 3 N=130 MEmbranous Nephropathy Trial Of Rituximab

Idiopathic Membranous Nephropathy

Primary: Remission Status — 39; 13 Participants — p=0.001

Mayo Clinic Results Apr 2019 23.8% serious AE View details

Phase 3 N=106 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

Narcolepsy With Cataplexy

Primary: Change in Weekly Number of Cataplexy Attacks — 0.27; 12.71 number of attacks

Jazz Pharmaceuticals Results Apr 2019 1.5% serious AE View details

Phase 3 N=66 Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

Diabetes Prevention in Women After GDM Who Are at High-risk

Primary: Change in Body Weight — -21.5; -12.5; -4.4 kilograms — p=<0.032

Woman's Results Apr 2019 0.0% serious AE View details

Phase 3 N=779 A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Treatment-resistant Depression

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 90.1 Percentage of participants

Janssen Research & Development, LLC Results Apr 2019 3.6% serious AE View details

Phase 3 N=2,233 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

Myelofibrosis

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years — 2153; 830 Participants

Novartis Pharmaceuticals Results Apr 2019 37.2% serious AE View details

Phase 3 N=216 Methotrexate and Mycophenolate Mofetil for UVEITIS

Uveitis

Primary: Number of Participants Achieving Treatment Success at 6 Months (Phase I, 0-6 Months) — 64; 56 Participants

University of California, San Francisco Results Apr 2019 6.5% serious AE View details

Phase 3 N=138 A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

Depressive Disorder, Treatment-Resistant

Primary: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Mixed-Effects Model Using…

Janssen Research & Development, LLC Results Apr 2019 3.3% serious AE View details

Phase 3 N=238 A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Actinic Keratosis (AK)

Primary: Proportion of Subjects With Complete Clearance of AK Lesions at the End of Study Visit at 16 Weeks — 6; 9; 10; 7 Participants

Dr. Reddy's Laboratories Limited Results Apr 2019 0.8% serious AE View details

Phase 3 N=1,601 Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

Influenza

Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains…

Seqirus Results Apr 2019 2.3% serious AE View details

Phase 3 N=40 Glutamatergic Modulation of Disordered Alcohol Use

Alcohol Dependence

Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants

New York State Psychiatric Institute Results Apr 2019 0.0% serious AE View details

Phase 3 N=288 MSB11022 in Moderate to Severe Rheumatoid Arthritis

Moderate to Severe Rheumatoid Arthritis

Primary: Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI) — 4.2; 5.5 Percentage of Participants

Fresenius Kabi SwissBioSim GmbH Results Apr 2019 8.0% serious AE View details